TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Feasibility Study for a Randomised Controlled Trial of Pelvic Floor Muscle Training Combined With Vaginal Pessary for Women With Pelvic Organ Prolapse.
Brief Summary: 1. To determine the feasibility of conducting a randomised controlled trial (RCT) of the effectiveness of a PFMT intervention in conjunction with vaginal pessary management versus vaginal pessary management alone for women with pelvic organ prolapse.
2. To develop and test the methods for a main trial.

The ultimate aim of a large multi-centre RCT would be to answer the question:

Is conservative management of pelvic organ prolapse with an individualised PFMT intervention in conjunction with vaginal pessary more effective than vaginal pessary alone in reducing prolapse-specific symptoms, prolapse severity and the need for further prolapse treatment?


Options:
A: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)
B: Arm Label: Study Group on estriol vaginal gel; Type: ACTIVE_COMPARATOR; Interventions: Drug: estriol, Procedure: vaginal surgery | Arm Label: Control group, no estriol treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: vaginal surgery | Intervention Type: DRUG; Name: estriol; Assigned to Arm(s): Study Group on estriol vaginal gel | Intervention Type: PROCEDURE; Name: vaginal surgery; Assigned to Arm(s): Control group, no estriol treatment, Study Group on estriol vaginal gel
C: Arm Label: PFMT plus routine pessary management; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Arm Label: Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Other: PFMT | Intervention Type: OTHER; Name: PFMT; Assigned to Arm(s): Lifestyle, PFMT plus routine pessary management
D: Arm Label: Premarin cream 0.5gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 0.5gm | Arm Label: Premarin cream 1.0gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 1.0gm | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 0.5gm; Assigned to Arm(s): Premarin cream 0.5gm | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 1.0gm; Assigned to Arm(s): Premarin cream 1.0gm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus
Brief Summary: Ubiquitous healthcare service for elderly patients with type 2 diabetes provides real-time glycemic monitoring and glucose control implemented by clinical decision support system (CDSS) using wire and wireless communication and information technology.

To evaluate the clinical efficacy of this system, researchers plan to compare the improvement of glycemic control, self-management, and quality of life among three study groups: control, self glucose monitoring, and U-healthcare group.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
B: Intervention Type: DEVICE; Name: OneTouch(r) UltraSmart(r); Assigned to Arm(s): N/A
C: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
D: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus
Brief Summary: Ubiquitous healthcare service for elderly patients with type 2 diabetes provides real-time glycemic monitoring and glucose control implemented by clinical decision support system (CDSS) using wire and wireless communication and information technology.

To evaluate the clinical efficacy of this system, researchers plan to compare the improvement of glycemic control, self-management, and quality of life among three study groups: control, self glucose monitoring, and U-healthcare group.


Options:
A: Arm Label: Exercise Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity counseling | Arm Label: Contact Control; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity counseling; Assigned to Arm(s): Exercise Counseling
B: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
C: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: telemedicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telemedicine; Assigned to Arm(s): telemedicine
D: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Efficacy of Ubiquitous Healthcare System for Elderly Patients With Type 2 Diabetes Mellitus
Brief Summary: Ubiquitous healthcare service for elderly patients with type 2 diabetes provides real-time glycemic monitoring and glucose control implemented by clinical decision support system (CDSS) using wire and wireless communication and information technology.

To evaluate the clinical efficacy of this system, researchers plan to compare the improvement of glycemic control, self-management, and quality of life among three study groups: control, self glucose monitoring, and U-healthcare group.


Options:
A: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
B: Arm Label: telemedicine; Type: EXPERIMENTAL; Interventions: Behavioral: telemedicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: telemedicine; Assigned to Arm(s): telemedicine
C: Arm Label: Intervention phone call; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Phone Call | Arm Label: Control arm - usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention Phone Call; Assigned to Arm(s): Intervention phone call
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Educational Intervention | Arm Label: No Intervention Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational Intervention; Assigned to Arm(s): Intervention Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Parallel-group Study to Assess the Efficacy and Safety of Double-blind Pasireotide LAR 40 mg and Pasireotide LAR 60 mg Versus Open-label Octreotide LAR or Lanreotide ATG in Patients With Inadequately Controlled Acromegaly
Brief Summary: This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.


Options:
A: Arm Label: Pasireotide LAR 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Pasireotide LAR 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Control arm (octreotide or lanreotide); Type: ACTIVE_COMPARATOR; Interventions: Drug: octreotide LAR 30mg, Drug: lanreotide ATG 120mg | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR 40 mg, Pasireotide LAR 60 mg | Intervention Type: DRUG; Name: octreotide LAR 30mg; Assigned to Arm(s): Control arm (octreotide or lanreotide) | Intervention Type: DRUG; Name: lanreotide ATG 120mg; Assigned to Arm(s): Control arm (octreotide or lanreotide)
B: Arm Label: Pasireotide LAR; Type: EXPERIMENTAL; Interventions: Drug: Pasireotide | Arm Label: Octreotide LAR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Octreotide | Intervention Type: DRUG; Name: Pasireotide; Assigned to Arm(s): Pasireotide LAR | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide LAR
C: Arm Label: CAM2029 10 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (NET); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 10 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Arm Label: CAM2029 20 mg (Acromegaly); Type: EXPERIMENTAL; Interventions: Drug: octreotide FluidCrystal® injection depot | Intervention Type: DRUG; Name: octreotide FluidCrystal® injection depot; Assigned to Arm(s): CAM2029 10 mg (Acromegaly), CAM2029 10 mg (NET), CAM2029 20 mg (Acromegaly), CAM2029 20 mg (NET)
D: Arm Label: Lanreotide autogel 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Lanreotide autogel 120 mg | Intervention Type: DRUG; Name: Lanreotide autogel 120 mg; Assigned to Arm(s): Lanreotide autogel 120 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Clinical Trial Comparing Efficacy Surgical Versus Medical Treatment of Osteomyelitis in Diabetic Foot Ulcers
Brief Summary: Hypothesis:Surgical treatment of osteomyelitis in diabetic foot is more effective that medical treatment through antibiotherapy and leads wound healing in ulcers complicated with bone infection.Material and Methods: Randomized clinical trials which include two groups of patients (n=88), one receives medical treatment through antibiotherapy during 90 days and the other group receive conservative surgical treatment and antibiotics during 7 days after surgery. It will be studied differences between both groups in healing time, recidives, present and relationship of adverse events and outflow of quality of life related health .


Options:
A: Arm Label: Patients undergoing medical treatment; Type: OTHER; Interventions: Drug: Ciprofloxacin, Drug: Amoxicillin-Potassium Clavulanate Combination, Drug: Sulfamethoxazole trimethoprim | Arm Label: Patients undergoing surgical treatment; Type: OTHER; Interventions: Procedure: Conservative surgery | Intervention Type: PROCEDURE; Name: Conservative surgery; Assigned to Arm(s): Patients undergoing surgical treatment | Intervention Type: DRUG; Name: Ciprofloxacin; Assigned to Arm(s): Patients undergoing medical treatment | Intervention Type: DRUG; Name: Amoxicillin-Potassium Clavulanate Combination; Assigned to Arm(s): Patients undergoing medical treatment | Intervention Type: DRUG; Name: Sulfamethoxazole trimethoprim; Assigned to Arm(s): Patients undergoing medical treatment
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge and levofloxacin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin only | Intervention Type: DRUG; Name: gentamicin-collagen sponge and levofloxacin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Levofloxacin only; Assigned to Arm(s): B
C: Arm Label: ofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ofloxacin | Arm Label: MSI-78; Type: ACTIVE_COMPARATOR; Interventions: Drug: MSI-78 | Intervention Type: DRUG; Name: ofloxacin; Assigned to Arm(s): ofloxacin | Intervention Type: DRUG; Name: MSI-78; Assigned to Arm(s): MSI-78
D: Arm Label: ofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ofloxacin | Arm Label: MSI-78; Type: ACTIVE_COMPARATOR; Interventions: Drug: MSI-78 | Intervention Type: DRUG; Name: ofloxacin; Assigned to Arm(s): ofloxacin | Intervention Type: DRUG; Name: MSI-78; Assigned to Arm(s): MSI-78

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease
Brief Summary: Vascular access complications are the leading cause of morbidity in hemodialysis (HD) patients, and are responsible for a significant percentage of hospitalization, with annual costs approaching one billion dollars in the United States. Thrombosis is the most common cause of vascular access failure, and usually develops from stenotic lesions in the venous outflow tract. It has been reported that far infrared (FIR) therapy can improve access flow and unassisted patency of AV fistula, however, the effect of FIR on cardiac function is unknown.

The aims of this study are to evaluate (1) the change of access flow of AV fistula and the effect of AV fistula on echocardiographic parameters and (2) the effect of FIR on access flow of AVF and echocardiographic parameters and the serum levels of endothelial markers in patients with end stage renal disease (ESRD) during the first 6 months after the creation of AV fistula.


Options:
A: Arm Label: GTN patch; Type: EXPERIMENTAL; Interventions: Drug: GTN patch | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo comparator | Intervention Type: DRUG; Name: GTN patch; Assigned to Arm(s): GTN patch | Intervention Type: DRUG; Name: placebo comparator; Assigned to Arm(s): Placebo patch
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201; Type: EXPERIMENTAL; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: Far infrared therapy; Type: EXPERIMENTAL; Interventions: Device: WSTM TY101 FIR emitter (Far infrared therapy) | Intervention Type: DEVICE; Name: WSTM TY101 FIR emitter (Far infrared therapy); Assigned to Arm(s): Far infrared therapy | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): control group
D: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease
Brief Summary: Vascular access complications are the leading cause of morbidity in hemodialysis (HD) patients, and are responsible for a significant percentage of hospitalization, with annual costs approaching one billion dollars in the United States. Thrombosis is the most common cause of vascular access failure, and usually develops from stenotic lesions in the venous outflow tract. It has been reported that far infrared (FIR) therapy can improve access flow and unassisted patency of AV fistula, however, the effect of FIR on cardiac function is unknown.

The aims of this study are to evaluate (1) the change of access flow of AV fistula and the effect of AV fistula on echocardiographic parameters and (2) the effect of FIR on access flow of AVF and echocardiographic parameters and the serum levels of endothelial markers in patients with end stage renal disease (ESRD) during the first 6 months after the creation of AV fistula.


Options:
A: Arm Label: PRT 201 (10 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201 (30 micrograms); Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT 201 (10 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 (30 micrograms)
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: Other: no intervention | Arm Label: Far infrared therapy; Type: EXPERIMENTAL; Interventions: Device: WSTM TY101 FIR emitter (Far infrared therapy) | Intervention Type: DEVICE; Name: WSTM TY101 FIR emitter (Far infrared therapy); Assigned to Arm(s): Far infrared therapy | Intervention Type: OTHER; Name: no intervention; Assigned to Arm(s): control group
C: Arm Label: Aggrenox; Type: EXPERIMENTAL; Interventions: Drug: Aggrenox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aggrenox; Assigned to Arm(s): Aggrenox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Cholecalciferol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Neonatal Vitamin A Supplementation in Improving Child Survival in Haryana, India: Generation of Evidence Necessary for Informing Global Policy
Brief Summary: The study is a large randomized controlled trial to assess the efficacy and safety of neonatal vitamin A supplementation administered to neonates once orally either on the day of birth or in the next 2 days in improving infant survival in the first 6 months of life.


Options:
A: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Drug: Vitamin A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vitamin A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): Placebo, Vitamin A
B: Arm Label: Low birth-weight cohort; Type: N/A; Interventions: N/A
C: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Arm Label: Vitamin A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU) | Intervention Type: DIETARY_SUPPLEMENT; Name: vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU); Assigned to Arm(s): Placebo, Vitamin A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multi-Center Trial of Lateral Trendelenburg Versus Semi-Recumbent Body Position in Mechanically Ventilated Patients For The Prevention of Ventilator-Associated Pneumonia
Brief Summary: This study is planned to compare, in patients sedated, intubated and mechanically ventilated, the efficacy and safety of the Lateral Trendelenburg position in comparison to the Semirecumbent Position to prevent incidence of ventilator-associated pneumonia (VAP).


Options:
A: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Procedure: Trendelenburg position | Intervention Type: PROCEDURE; Name: Trendelenburg position; Assigned to Arm(s): Single arm
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
C: Arm Label: Semirecumbent position; Type: ACTIVE_COMPARATOR; Interventions: Other: lateral-Trendelenburg position | Arm Label: lateral-Trendelenburg position; Type: EXPERIMENTAL; Interventions: Other: lateral-Trendelenburg position | Intervention Type: OTHER; Name: lateral-Trendelenburg position; Assigned to Arm(s): Semirecumbent position, lateral-Trendelenburg position
D: Arm Label: Repetitive recruitment with PEEP; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive recruitment with PEEP | Arm Label: One recruitment with PEEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: One recruitment with PEEP | Intervention Type: PROCEDURE; Name: Repetitive recruitment with PEEP; Assigned to Arm(s): Repetitive recruitment with PEEP | Intervention Type: PROCEDURE; Name: One recruitment with PEEP; Assigned to Arm(s): One recruitment with PEEP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I/II Dose-escalation Study of the Investigational Trifunctional Bispecific Anti-CD20 x Anti-CD3 Antibody FBTA05 in Combination With Donor Lymphocyte Infusion (DLI) in Patients With CD20 Positive Chronic Lymphocytic Leukemia (CLL), Low and High Grade Non-Hodgkin´s Lymphoma (NHL) After Allogeneic Stem Cell Transplantation
Brief Summary: This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with donor lymphocyte infusions (DLI) for treatment of relapsed or refractory disease in CD20 positive either low- or high-grade non-Hodgkin´s lymphoma after allogeneic transplantation


Options:
A: Arm Label: CD19-CART01; Type: EXPERIMENTAL; Interventions: Biological: CD19-CAR T cell | Intervention Type: BIOLOGICAL; Name: CD19-CAR T cell; Assigned to Arm(s): CD19-CART01
B: Arm Label: CD30 positive NHL subtypes; Type: EXPERIMENTAL; Interventions: Drug: CD30.CAR-T | Intervention Type: DRUG; Name: CD30.CAR-T; Assigned to Arm(s): CD30 positive NHL subtypes
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FBTA05 | Intervention Type: DRUG; Name: FBTA05; Assigned to Arm(s): 1
D: Intervention Type: PROCEDURE; Name: Procedure - Adoptive cell transfer; Assigned to Arm(s): N/A

Answer: C